Parkinson’s patients ‘owed’ more research into using cancer drug as treatment

News

Author: AdminPublished: 2 November 2015

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

A small clinical trial showed that cancer drug Nilotinib may reverse late-stage Parkinson’s disease, potentially enabling participants to speak and walk again for the first time in years.

President and co-founder of The Cure Parkinson’s Trust, Tom Isaacs, has called for a close follow up of this small study to ensure that any opportunity for a breakthrough in the treatment of Parkinson’s is not missed.

Isaacs said: ‘Nilotinib is a case in point. When people with Parkinson’s volunteer for clinical trials and feel the type of marked improvements to their symptoms and wellbeing as those reported in this study, we owe it to them, and indeed everyone, to follow the results up as quickly and as rigorously as possible.”

Go Back

Share this story

Comments


Related articles


Perspectives

Billy Connolly: “Parkinson’s is the first thing I think about in the morning”

Scottish comedian opens up about his Parkinson’s awards ceremony

READ MORE
blog

Interviews

“I hope people take away hope and a smile from my blog”

The latest in our monthly series

READ MORE
Bike

Interviews

Pedalling for Parkinson’s

We talk to the founder of The Bike Box Project in New Bern, North Carolina

READ MORE